Zentalis Pharmaceuticals Inc (ZNTL)

$4.05 -0.20 (-4.71%)
Market Cap 282.31M
Revenue (ttm) 0.00
Net Income (ttm) -137.06M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,182,300
Avg Vol 2,216,356
Day's Range N/A - N/A
Shares Out 70.93M
Stochastic %K 19%
Beta 1.65
Analysts Sell
Price Target $6.25

Company Profile

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. The company develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. It also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib...

Industry: Biotechnology
Sector: Healthcare
Phone: 212 433 3791
Address:
10275 Science Center Dr., Suite 200, San Diego, United States
AbovetheGreenLine
AbovetheGreenLine Apr. 27 at 7:10 PM
Swing Trade Buy on the Close for Zentalis Pharma. $ZNTL. https://abovethegreenline.com/wp-content/uploads/2021/01/ST-1.jpg https://zpr.io/z
0 · Reply
Snackdaddy
Snackdaddy Apr. 24 at 1:40 PM
$ZNTL wow. still dropping didnt see this going back to $2S but maybe
1 · Reply
Snackdaddy
Snackdaddy Apr. 22 at 6:03 PM
$ZNTL still getting beat up. can this actually retrace to $2S?
0 · Reply
Stef_Gee
Stef_Gee Apr. 22 at 11:29 AM
$ZNTL That was the original one ... 😉
1 · Reply
Stef_Gee
Stef_Gee Apr. 22 at 11:26 AM
$ZNTL 🫡
0 · Reply
Stef_Gee
Stef_Gee Apr. 22 at 11:22 AM
$ZNTL Again ... 😏
0 · Reply
GSP
GSP Apr. 21 at 8:26 PM
$GLND $BIRD $XNDU $WSHP $ZNTL
0 · Reply
focafoca99
focafoca99 Apr. 21 at 4:51 PM
$ZNTL is taking ASCO data on azenosertib plus paclitaxel in platinum-resistant ovarian cancer as it keeps building the WEE1 inhibitor program.
0 · Reply
laurenlee
laurenlee Apr. 21 at 3:51 PM
$BBGI $CHOW $DKI $VTAK $ZNTL
1 · Reply
laurenlee
laurenlee Apr. 21 at 3:46 PM
$BBGI $CHOW $DKI $VTAK $ZNTL
0 · Reply
Latest News on ZNTL
Zentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian Cancer

Apr 21, 2026, 10:27 AM EDT - 8 days ago

Zentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian Cancer

Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026

Apr 17, 2026, 3:15 PM EDT - 11 days ago

Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026

What's Behind The Surge In Zentalis Stock?

Apr 10, 2026, 12:44 PM EDT - 19 days ago

What's Behind The Surge In Zentalis Stock?

Zentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer

Apr 9, 2026, 8:00 AM EDT - 20 days ago

Zentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 1, 2026, 5:00 PM EDT - 27 days ago

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational Updates

Mar 26, 2026, 4:05 PM EDT - 4 weeks ago

Zentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational Updates

Zentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026

Mar 17, 2026, 4:30 PM EDT - 6 weeks ago

Zentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026

Zentalis Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 1:00 PM EDT - 7 weeks ago

Zentalis Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026

Zentalis Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 10:30 AM EST - 2 months ago

Zentalis Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Zentalis Pharmaceuticals Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 25, 2026, 12:40 PM EST - 2 months ago

Zentalis Pharmaceuticals Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

Feb 18, 2026, 8:00 AM EST - 2 months ago

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

Zentalis Pharmaceuticals Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 11, 2026, 3:30 PM EST - 2 months ago

Zentalis Pharmaceuticals Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conference

Feb 3, 2026, 4:05 PM EST - 3 months ago

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conference

Zentalis Pharmaceuticals Provides Corporate Update and Highlights Key Milestones and Expected Momentum in the Azenosertib Development Program for 2026

Jan 6, 2026, 8:00 AM EST - 4 months ago

Zentalis Pharmaceuticals Provides Corporate Update and Highlights Key Milestones and Expected Momentum in the Azenosertib Development Program for 2026

Zentalis Pharmaceuticals Transcript: Stifel 2025 Healthcare Conference

Nov 12, 2025, 8:00 AM EST - 6 months ago

Zentalis Pharmaceuticals Transcript: Stifel 2025 Healthcare Conference

Zentalis Pharmaceuticals Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 11, 2025, 3:30 PM EST - 6 months ago

Zentalis Pharmaceuticals Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Zentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Progress

Nov 10, 2025, 4:05 PM EST - 6 months ago

Zentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Progress

Zentalis Pharmaceuticals Announces Four Azenosertib Posters Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 13, 2025, 4:05 PM EDT - 7 months ago

Zentalis Pharmaceuticals Announces Four Azenosertib Posters Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Zentalis Pharmaceuticals Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 9, 2025, 7:00 AM EDT - 8 months ago

Zentalis Pharmaceuticals Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Zentalis Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 2:30 PM EDT - 8 months ago

Zentalis Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Zentalis Pharmaceuticals Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 4, 2025, 10:15 AM EDT - 8 months ago

Zentalis Pharmaceuticals Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Zentalis Pharmaceuticals Appoints James B. Bucher, JD, as Chief Legal Officer and Corporate Secretary

Aug 26, 2025, 4:05 PM EDT - 8 months ago

Zentalis Pharmaceuticals Appoints James B. Bucher, JD, as Chief Legal Officer and Corporate Secretary

Zentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Progress

Aug 6, 2025, 4:05 PM EDT - 9 months ago

Zentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Progress

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jul 1, 2025, 5:00 PM EDT - 10 months ago

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Zentalis Pharmaceuticals Transcript: Jefferies Global Life Sciences Conference

Jun 4, 2025, 9:55 AM EDT - 11 months ago

Zentalis Pharmaceuticals Transcript: Jefferies Global Life Sciences Conference

Zentalis Pharmaceuticals Transcript: TD Cowen's 6th Annual Oncology Innovation Summit

May 27, 2025, 11:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals Transcript: TD Cowen's 6th Annual Oncology Innovation Summit

Zentalis Pharmaceuticals Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 20, 2025, 11:30 AM EDT - 1 year ago

Zentalis Pharmaceuticals Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress

May 14, 2025, 4:05 PM EDT - 1 year ago

Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress

Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC

Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting

Apr 23, 2025, 4:05 PM EDT - 1 year ago

Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting

Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates

Mar 26, 2025, 4:05 PM EDT - 1 year ago

Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates

Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025

Mar 25, 2025, 4:40 PM EDT - 1 year ago

Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025

Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer

Mar 15, 2025, 11:25 AM EDT - 1 year ago

Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer

Zentalis Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2025

Mar 10, 2025, 9:20 AM EDT - 1 year ago

Zentalis Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2025

Zentalis Pharmaceuticals Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 3, 2025, 11:50 AM EST - 1 year ago

Zentalis Pharmaceuticals Transcript: TD Cowen 45th Annual Healthcare Conference

Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer

Mar 3, 2025, 8:00 AM EST - 1 year ago

Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer

Zentalis Pharmaceuticals Transcript: Study Update

Jan 29, 2025, 8:00 AM EST - 1 year ago

Zentalis Pharmaceuticals Transcript: Study Update

Zentalis Pharmaceuticals Shares Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer

Jan 29, 2025, 7:00 AM EST - 1 year ago

Zentalis Pharmaceuticals Shares Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer

Zentalis Pharmaceuticals Announces Strategic Restructuring to Support Late-Stage Azenosertib Development

Jan 28, 2025, 4:05 PM EST - 1 year ago

Zentalis Pharmaceuticals Announces Strategic Restructuring to Support Late-Stage Azenosertib Development

Zentalis Pharmaceuticals Announces Azenosertib Fast Track Designation and Virtual Corporate Event to Present Updated Data from Azenosertib Clinical Studies

Jan 9, 2025, 7:00 AM EST - 1 year ago

Zentalis Pharmaceuticals Announces Azenosertib Fast Track Designation and Virtual Corporate Event to Present Updated Data from Azenosertib Clinical Studies

Zentalis Pharmaceuticals Announces Key Management Appointments

Dec 12, 2024, 7:00 AM EST - 1 year ago

Zentalis Pharmaceuticals Announces Key Management Appointments

Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm

Nov 21, 2024, 1:14 PM EST - 1 year ago

Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm

FMR LLC Adjusts Its Stake in Zentalis Pharmaceuticals Inc

Oct 7, 2024, 2:03 PM EDT - 1 year ago

FMR LLC Adjusts Its Stake in Zentalis Pharmaceuticals Inc

FDA Removes Partial Hold On Zentalis Pharmaceuticals' Azenosertib Studies In Patients With Gynecological Cancers

Sep 16, 2024, 9:00 AM EDT - 1 year ago

FDA Removes Partial Hold On Zentalis Pharmaceuticals' Azenosertib Studies In Patients With Gynecological Cancers

Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies

Sep 16, 2024, 7:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies

Zentalis Pharmaceuticals to Present Preclinical Azenosertib Data at ESMO 2024

Sep 9, 2024, 7:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals to Present Preclinical Azenosertib Data at ESMO 2024

Newman Ferrara LLP Announces Corporate Governance Investigation of Zentalis Pharmaceuticals, Inc. – ZNTL

Aug 19, 2024, 4:55 PM EDT - 1 year ago

Newman Ferrara LLP Announces Corporate Governance Investigation of Zentalis Pharmaceuticals, Inc. – ZNTL

Investors In Zentalis Pharmaceuticals Inc Encouraged To Participate In Fraud Investigation With The Schall Law Firm

Aug 19, 2024, 11:00 AM EDT - 1 year ago

Investors In Zentalis Pharmaceuticals Inc Encouraged To Participate In Fraud Investigation With The Schall Law Firm

Shareholders With Losses In Zentalis Pharmaceuticals Inc Invited To Join Fraud Investigation With Schall Law Firm

Aug 18, 2024, 11:00 AM EDT - 1 year ago

Shareholders With Losses In Zentalis Pharmaceuticals Inc Invited To Join Fraud Investigation With Schall Law Firm

Zentalis Pharmaceuticals Inc Investors Asked To Partake In Fraud Investigation With Schall Law Firm

Aug 17, 2024, 11:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals Inc Investors Asked To Partake In Fraud Investigation With Schall Law Firm

Zentalis Pharmaceuticals Inc Stockholders Invited To Join In Fraud Investigation With Schall Law Firm

Aug 16, 2024, 11:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals Inc Stockholders Invited To Join In Fraud Investigation With Schall Law Firm

Zentalis Pharmaceuticals, Inc. (ZNTL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Aug 15, 2024, 4:00 PM EDT - 1 year ago

Zentalis Pharmaceuticals, Inc. (ZNTL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Zentalis Pharmaceuticals Inc Investors Welcome To Join Fraud Investigation With Schall Law Firm

Aug 15, 2024, 11:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals Inc Investors Welcome To Join Fraud Investigation With Schall Law Firm

Zentalis Pharmaceuticals Inc Shareholders Invited To Join Fraud Investigation With Schall Law Firm

Aug 14, 2024, 10:30 PM EDT - 1 year ago

Zentalis Pharmaceuticals Inc Shareholders Invited To Join Fraud Investigation With Schall Law Firm

Zentalis Pharmaceuticals Transcript: Study Update

Jun 18, 2024, 8:00 AM EDT - 2 years ago

Zentalis Pharmaceuticals Transcript: Study Update

Zentalis Pharmaceuticals Transcript: TD Cowen 5th Annual Oncology Innovation Virtual Summit

May 28, 2024, 10:30 AM EDT - 2 years ago

Zentalis Pharmaceuticals Transcript: TD Cowen 5th Annual Oncology Innovation Virtual Summit

Zentalis Pharmaceuticals Transcript: Leerink Partners Global Biopharma Conference 2024

Mar 11, 2024, 3:20 PM EDT - 2 years ago

Zentalis Pharmaceuticals Transcript: Leerink Partners Global Biopharma Conference 2024

Zentalis Pharmaceuticals Transcript: TD Cowen 44th Annual Health Care Conference

Mar 5, 2024, 10:30 AM EST - 2 years ago

Zentalis Pharmaceuticals Transcript: TD Cowen 44th Annual Health Care Conference

Zentalis Pharmaceuticals Transcript: Oppenheimer 34th Annual Healthcare Life Sciences Conference (Virtual)

Feb 14, 2024, 12:40 PM EST - 2 years ago

Zentalis Pharmaceuticals Transcript: Oppenheimer 34th Annual Healthcare Life Sciences Conference (Virtual)

Zentalis Pharmaceuticals Transcript: 14th Annual Jefferies London Healthcare Conference 2023

Nov 15, 2023, 3:30 AM EST - 2 years ago

Zentalis Pharmaceuticals Transcript: 14th Annual Jefferies London Healthcare Conference 2023

Zentalis Pharmaceuticals Transcript: Investor Update

Nov 10, 2023, 10:00 AM EST - 2 years ago

Zentalis Pharmaceuticals Transcript: Investor Update

Zentalis Pharmaceuticals Transcript: Morgan Stanley 21st Annual Global Healthcare Conference 2023

Sep 13, 2023, 10:10 AM EDT - 2 years ago

Zentalis Pharmaceuticals Transcript: Morgan Stanley 21st Annual Global Healthcare Conference 2023

Zentalis Pharmaceuticals Transcript: Study Update

Jun 6, 2023, 8:00 AM EDT - 3 years ago

Zentalis Pharmaceuticals Transcript: Study Update

Zentalis Pharmaceuticals Transcript: Guggenheim Healthcare Talks Oncology Day

Feb 8, 2023, 9:00 AM EST - 3 years ago

Zentalis Pharmaceuticals Transcript: Guggenheim Healthcare Talks Oncology Day

Zentalis Pharmaceuticals Transcript: Morgan Stanley 20th Annual Global Healthcare Conference 2022

Sep 14, 2022, 10:35 AM EDT - 3 years ago

Zentalis Pharmaceuticals Transcript: Morgan Stanley 20th Annual Global Healthcare Conference 2022

Zentalis Pharmaceuticals Transcript: AACR Day 2022

Apr 8, 2022, 4:00 PM EDT - 4 years ago

Zentalis Pharmaceuticals Transcript: AACR Day 2022

Zentalis Pharmaceuticals Transcript: R&D Day 2021

Dec 16, 2021, 11:00 AM EST - 4 years ago

Zentalis Pharmaceuticals Transcript: R&D Day 2021

AbovetheGreenLine
AbovetheGreenLine Apr. 27 at 7:10 PM
Swing Trade Buy on the Close for Zentalis Pharma. $ZNTL. https://abovethegreenline.com/wp-content/uploads/2021/01/ST-1.jpg https://zpr.io/z
0 · Reply
Snackdaddy
Snackdaddy Apr. 24 at 1:40 PM
$ZNTL wow. still dropping didnt see this going back to $2S but maybe
1 · Reply
Snackdaddy
Snackdaddy Apr. 22 at 6:03 PM
$ZNTL still getting beat up. can this actually retrace to $2S?
0 · Reply
Stef_Gee
Stef_Gee Apr. 22 at 11:29 AM
$ZNTL That was the original one ... 😉
1 · Reply
Stef_Gee
Stef_Gee Apr. 22 at 11:26 AM
$ZNTL 🫡
0 · Reply
Stef_Gee
Stef_Gee Apr. 22 at 11:22 AM
$ZNTL Again ... 😏
0 · Reply
GSP
GSP Apr. 21 at 8:26 PM
$GLND $BIRD $XNDU $WSHP $ZNTL
0 · Reply
focafoca99
focafoca99 Apr. 21 at 4:51 PM
$ZNTL is taking ASCO data on azenosertib plus paclitaxel in platinum-resistant ovarian cancer as it keeps building the WEE1 inhibitor program.
0 · Reply
laurenlee
laurenlee Apr. 21 at 3:51 PM
$BBGI $CHOW $DKI $VTAK $ZNTL
1 · Reply
laurenlee
laurenlee Apr. 21 at 3:46 PM
$BBGI $CHOW $DKI $VTAK $ZNTL
0 · Reply
laurenlee
laurenlee Apr. 21 at 3:36 PM
$BBGI $CHOW $DKI $VTAK $ZNTL
0 · Reply
laurenlee
laurenlee Apr. 21 at 3:14 PM
$BBGI $CHOW $DKI $VTAK $ZNTL
0 · Reply
laurenlee
laurenlee Apr. 21 at 2:56 PM
$BBGI $CHOW $DKI $VTAK $ZNTL
0 · Reply
lucabrix
lucabrix Apr. 21 at 9:10 AM
$ZNTL Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) is one of the must-buy small cap stocks to buy. On April 10, Jefferies raised its price target on Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) from $2.50 to $6.00 and left the Hold rating unchanged. This decision came after Zentalis said it had selected the optimal dose of its lead cancer drug azenosertib based on interim data from an ongoing clinical trial.
0 · Reply
GSP
GSP Apr. 21 at 2:23 AM
$WSHP $ZNTL $SIDU $MNTS
0 · Reply
Sillyspuh
Sillyspuh Apr. 20 at 3:20 PM
$ZNTL Nice entry point in the low 4's, I suspect
2 · Reply
zawojak
zawojak Apr. 20 at 2:19 PM
$ZNTL WOOW POS of the week
0 · Reply
Stef_Gee
Stef_Gee Apr. 20 at 11:33 AM
$ZNTL
0 · Reply
GSP
GSP Apr. 20 at 1:33 AM
$BIRD $CRML $ICG $WSHP $ZNTL
0 · Reply
Sillyspuh
Sillyspuh Apr. 17 at 9:28 PM
$ZNTL Nice update on pre-clinical combo findings for breast cancer. I'm not sure how much these pre-clinical announcements move the needle. https://ir.zentalis.com/news-releases/news-release-details/zentalis-pharmaceuticals-present-azenosertib-preclinical-data
1 · Reply
focafoca99
focafoca99 Apr. 17 at 8:02 PM
$ZNTL shared AACR data showing azenosertib combinations drove strong preclinical activity in ADC-resistant TNBC and highlighted poorer outcomes in Cyclin E1-positive ovarian cancer patients.
0 · Reply
isa_32
isa_32 Apr. 17 at 3:22 PM
$RUBI $RAYA $ZNTL $AIXI
0 · Reply